Short Interest in Mainz Biomed NV (NASDAQ:QUCY) Declines By 85.5%

Mainz Biomed NV (NASDAQ:QUCY) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 1,522,115 shares, a decline of 85.5% from the May 14th total of 10,530,990 shares. Approximately 10.7% of the shares of the stock are sold short. Based on an average daily volume of 15,034,560 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings raised Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Maxim Group cut shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Mainz Biomed presently has a consensus rating of “Reduce”.

Mainz Biomed Price Performance

Shares of NASDAQ QUCY opened at $1.90 on Friday. The firm has a market cap of $27.86 million, a price-to-earnings ratio of -0.04 and a beta of 2.22. Mainz Biomed has a one year low of $0.30 and a one year high of $4.93. The business’s 50-day simple moving average is $1.43.

Mainz Biomed (NASDAQ:QUCY) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.02) EPS for the quarter. The company had revenue of $0.13 million for the quarter.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.